Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 2
2010 1
2014 1
2015 1
2017 2
2018 1
2019 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.
Pinto A, Corradini P, Mussetti A, Zinzani PL. Pinto A, et al. Leuk Lymphoma. 2015 Jul;56(7):1969-74. doi: 10.3109/10428194.2014.981174. Epub 2014 Dec 4. Leuk Lymphoma. 2015. PMID: 25363402 Review.
In fact, a negative PET status before ASCT is a well-known positive prognostic factor in patients with RR-HL. The recent introduction of the biologically targeted agent brentuximab vedotin has allowed us to treat RR-HL more efficaciously with less toxicity for the patient. …
In fact, a negative PET status before ASCT is a well-known positive prognostic factor in patients with RR-HL. The recent introduction …
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL. Jacene H, et al. Mol Imaging Biol. 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9. Mol Imaging Biol. 2017. PMID: 27798787 Clinical Trial.
Twelve weeks after [(131)I]tositumomab, 10 patients progressed and two with LPHL achieved complete response. [(18)F]DG-PET/CT at 6 weeks post therapy appeared more predictive than CT at 6 weeks of a response at 12 weeks. CONCLUSIONS: Tositumomab and [(131)I]tositumomab was …
Twelve weeks after [(131)I]tositumomab, 10 patients progressed and two with LPHL achieved complete response. [(18)F]DG-PET/CT at 6 weeks pos …
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ. Smith EP, et al. Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28. Biol Blood Marrow Transplant. 2018. PMID: 29289757 Free PMC article. Clinical Trial.
The observed 5-year PFS of 55% suggests the tandem approach appears to be effective in treating HL patients demonstrated to have poor prognosis in prior single AHSCT trials. This trial was registered at www.clinicaltrials.gov as NCT00233987....
The observed 5-year PFS of 55% suggests the tandem approach appears to be effective in treating HL patients demonstrated to have poor pro …
Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.
Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ. Tinkle CL, et al. Radiother Oncol. 2019 May;134:89-95. doi: 10.1016/j.radonc.2019.01.026. Epub 2019 Feb 5. Radiother Oncol. 2019. PMID: 31005229 Free PMC article.
Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT. RESULTS: RT was administered as part of frontline therapy in 70% of patients, omitted for early response assess …
Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors …
Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.
Dodero A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F, Bramanti S, Frungillo N, Milani R, Crippa F, Fallanca F, Englaro E, Corradini P. Dodero A, et al. Cancer. 2010 Nov 1;116(21):5001-11. doi: 10.1002/cncr.25357. Cancer. 2010. PMID: 20665491 Free article.
BACKGROUND: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). ... …
BACKGROUND: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has …
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A. Tarella C, et al. Cancer. 2003 Jun 1;97(11):2748-59. doi: 10.1002/cncr.11414. Cancer. 2003. PMID: 12767087 Free article.
Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L, Deau-Fischer B, Franchi P, Arsène-Henry A, Cassou Mounat T, Bouscary D, Kirova YM. de Forceville L, et al. Cancer Radiother. 2019 Jun;23(3):232-239. doi: 10.1016/j.canrad.2018.12.005. Epub 2019 May 27. Cancer Radiother. 2019. PMID: 31147173
However about 50% of patients will have recurrence after high-dose chemotherapy followed by autologous stem cell rescue or transplantation and have worse prognosis with median overall survival of 32% at 5 years. The anti-PD1 checkpoints inhibitors pembrolizumab and nivolum …
However about 50% of patients will have recurrence after high-dose chemotherapy followed by autologous stem cell rescue or transplantation a …
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.
Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A. Fung HC, et al. Biol Blood Marrow Transplant. 2007 May;13(5):594-600. doi: 10.1016/j.bbmt.2007.01.072. Epub 2007 Mar 23. Biol Blood Marrow Transplant. 2007. PMID: 17448919 Free article. Clinical Trial.
ELIGIBILITY CRITERIA: primary progressive (n = 28) or recurrent HL (n = 18) with at least 1 of the following poor prognostic factors: first complete remission (CR) <12 months (n = 15) or extra-nodal disease (n = 4) or B symptoms at relapse (n = 4). ...
ELIGIBILITY CRITERIA: primary progressive (n = 28) or recurrent HL (n = 18) with at least 1 of the following poor prognostic factors: …
Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Schaefer NG, et al. Radiology. 2007 Jul;244(1):257-62. doi: 10.1148/radiol.2441060810. Radiology. 2007. PMID: 17581905
The presence of bulky disease (>5 cm) after the end of treatment was a significant predictor of recurrent disease (P<.05). CONCLUSION: The authors conclude that FDG PET/CT can help exclude persistent and/or recurrent Hodgkin lymphoma after first-line therapy. ...
The presence of bulky disease (>5 cm) after the end of treatment was a significant predictor of recurrent disease (P<.05). CONC …